{"id":482071,"date":"2020-05-01T11:48:02","date_gmt":"2020-05-01T11:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=482071"},"modified":"2020-05-01T11:48:02","modified_gmt":"2020-05-01T11:48:02","slug":"nonsmall-cell-lung-cancer-epidemiology-forecast-diagnosed-pool-incidence-and-segmentation-201730","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-epidemiology-forecast-diagnosed-pool-incidence-and-segmentation-201730_482071.html","title":{"rendered":"Non-Small Cell Lung Cancer Epidemiology Forecast: Diagnosed pool, Incidence, and Segmentation 2017-30"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588333814.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Non-Small Cell Lung Cancer Epidemiology Forecast: Diagnosed pool, Incidence, and Segmentation 2017-30\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588333814.jpeg\" alt=\"Non-Small Cell Lung Cancer Epidemiology Forecast: Diagnosed pool, Incidence, and Segmentation 2017-30\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Non-Small Cell Lung Cancer Epidemiology Forecast<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017-2030.<\/p>\n<p>DelveInsight&#8217;s &#8216;Non-Small Cell Lung Cancer &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM.<\/p><\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-epidemiology-forecast?utm_source=pr&amp;utm_campaign=vinita\">&#8216;Non-Small Cell Lung Cancer &#8211; Epidemiology Forecast to 2030&#8217;<\/a> report delivers an in-depth understanding of the disease, historical and forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Geography Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The United States<\/li>\n<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/li>\n<li>Japan<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Study Period<\/strong>: 2017-2030<\/p>\n<p style=\"text-align: justify;\"><strong>Non-Small Cell Lung Cancer Epidemiology <\/strong><\/p>\n<p style=\"text-align: justify;\">The Non-Small Cell Lung Cancer epidemiology division provides the insights about historical and current Non-Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n<p style=\"text-align: justify;\">As per the DelveInsight analysis, the <strong>total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017<\/strong>. These cases are expected to grow with a significant CAGR in the study period 2017&ndash;2030.<\/p>\n<p style=\"text-align: justify;\"><strong>Non-Small Cell Lung Cancer Epidemiology Segmentation <\/strong><\/p>\n<p style=\"text-align: justify;\">The disease epidemiology covered in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030 segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Incident cases of NSCLC patients,<\/li>\n<li>Total Incident cases of NSCLC patients by Histology,<\/li>\n<li>Total Diagnosed cases of NSCLC patients by Stages,<\/li>\n<li>Total NSCLC cases of patients by Genetic mutation\/Biomarkers, and<\/li>\n<li>Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/?utm_source=pr&amp;utm_campaign=vinita\">Visit to know more.<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Non-Small Cell Lung Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-Small Cell Lung Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-Small Cell Lung Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-epidemiology-forecast?utm_source=pr&amp;utm_campaign=vinita\">Request for sample pages.<\/a><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>11-Year Forecast of Non-Small Cell Lung Cancer epidemiology<\/li>\n<li>7MM Coverage<\/li>\n<li>Total Cases of Non-Small Cell Lung Cancer<\/li>\n<li>Total Cases of Non-Small Cell Lung Cancer according to segmentation<\/li>\n<li>Diagnosed cases of Non-Small Cell Lung Cancer<\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1.&nbsp;Key Insights<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Non-Small Cell Lung Cancer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3.&nbsp;Non-Small Cell Lung Cancer: Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4.&nbsp;Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5.&nbsp;Epidemiology and Patient Population<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>5.3.&nbsp;Epidemiology Scenario: 7MM<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>5.4.&nbsp;United States Epidemiology<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>5.5.&nbsp;EU-5 Country-wise Epidemiology<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>5.6. Japan Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7.&nbsp;KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8.&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9.&nbsp;&nbsp;Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10.&nbsp;DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11.&nbsp;Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><em><strong>*The table of contents is not exhaustive; will be provided in the final report<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=pr&amp;utm_medium=abnewswire&amp;utm_campaign=vinita\">DelveInsight<\/a><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.<\/p>\n<p style=\"text-align: justify;\">Browse through our vast repository from <a rel=\"nofollow\" href=\"https:\/\/delveinsight.com\/report-store.php?utm_source=pr&amp;utm_medium=abnewswire&amp;utm_campaign=vinita\">here<\/a>.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57049.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Vinita Rakheja <br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=nonsmall-cell-lung-cancer-epidemiology-forecast-diagnosed-pool-incidence-and-segmentation-201730\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=nonsmall-cell-lung-cancer-epidemiology-forecast-diagnosed-pool-incidence-and-segmentation-201730\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Non-Small Cell Lung Cancer Epidemiology Forecast As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-epidemiology-forecast-diagnosed-pool-incidence-and-segmentation-201730_482071.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-482071","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=482071"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482071\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=482071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=482071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=482071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}